Pfizer Inc. (NYSE:PFE) Stake Trimmed by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 55.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 203,518 shares of the biopharmaceutical company's stock after selling 254,639 shares during the period. O Shaughnessy Asset Management LLC's holdings in Pfizer were worth $5,399,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Bcwm LLC bought a new position in Pfizer in the fourth quarter valued at about $4,264,000. United Bank raised its stake in shares of Pfizer by 27.3% in the fourth quarter. United Bank now owns 45,331 shares of the biopharmaceutical company's stock worth $1,203,000 after buying an additional 9,732 shares during the period. Life Planning Partners Inc bought a new stake in Pfizer during the 4th quarter valued at approximately $893,000. Summit Securities Group LLC boosted its stake in Pfizer by 38.4% during the fourth quarter. Summit Securities Group LLC now owns 23,800 shares of the biopharmaceutical company's stock valued at $631,000 after buying an additional 6,600 shares during the last quarter. Finally, Schroder Investment Management Group increased its stake in Pfizer by 13.6% during the fourth quarter. Schroder Investment Management Group now owns 9,973,310 shares of the biopharmaceutical company's stock worth $264,592,000 after acquiring an additional 1,193,722 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PFE shares. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Price Performance

Shares of NYSE PFE traded down $0.41 during trading on Thursday, hitting $24.30. 53,412,700 shares of the company were exchanged, compared to its average volume of 39,300,271. The company has a market cap of $137.79 billion, a price-to-earnings ratio of 17.23, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1 year low of $24.26 and a 1 year high of $31.54. The firm's fifty day moving average price is $25.98 and its 200 day moving average price is $26.83. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.